Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1850Source: DataRank Database

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors is a research paper published in Annals of Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 0.09)OA: bronzeTopics (18)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

T. Khanh ORCID,James M. Cleary ORCID,Aparna R. Parikh ORCID,Oladapo Yeku ORCID,Colin D. Weekes ORCID

Live enrichment

PubMed:21097893 OpenAlex:https://openalex.org/W4387811495

FWCI

0.09

Citation Percentile

0.4%

Citation Trend

2025

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.annalsofoncology.org/article/S092375342302687X/pdf

publisherhttp://www.annalsofoncology.org/article/S092375342302687X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S092375342302687X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S092375342302687X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.annonc.2023.09.1850

Fields of Study

Melanoma and MAPK PathwaysCancer Treatment and PharmacologyLung Cancer Treatments and Mutations

Keywords

TrametinibKRASMedicineNeuroblastoma RAS viral oncogene homologMutantCancer researchMEK inhibitorOncologyInternal medicineGeneticsGeneMAPK/ERK pathwayCancerKinaseBiology

Sustainable Development Goals

SDG 0: Zero hunger